COVID-19 Vaccines Market Production Capacity & Development Timeline: (By Type: Virus-Like Particle (VLP), Whole Virus, Protein, Antibodies, Viral Vector, mRNA/DNA)Report

COVID-19 Vaccines Market Production Capacity & Development Timeline: (By Type: Virus-Like Particle (VLP), Whole Virus, Protein, Antibodies, Viral Vector, mRNA/DNA)

  • Report ID: GVR451011
  • Number of Pages: 50
  • Format: Electronic (PDF)

Table of Contents

Chapter 1 Methodology And Scope
                   1.1 Research Methodology
                   1.2 Research Assumptions
                       1.2.1 Estimates And Forecast Timeline
                   1.3 Information Procurement
                       1.3.1 Purchased Database
                       1.3.2 Gvr’s Internal Database
                       1.3.3 Secondary Sources
                       1.3.4 Primary Research
                       1.3.5 Details Of Primary Research
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis
                           1.6.1.1 Approach 1: Commodity Flow Approach
                       1.6.2 Volume Price Analysis (Model 2)
                           1.6.2.1 Approach 2: Volume Price Analysis
                           1.6.2.2 Revenue Modeling
                           1.6.2.3 Workflow Mapping Of COVID-19 Vaccines
                   1.7 List of Secondary Sources
                   1.8 List of Primary Sources
Chapter 2 Executive Summary
Chapter 3 Production Capacity & Competitive Analysis
                   3.1 Potential Vaccine Production Capacity
                   3.2 Approval Timeline
                       3.2.1 Evidence From Phase I And Phase Ii Trials
                       3.2.2 Vaccine Candidates By Technology Platform And Development Phase
                   3.3 Country Wise Investments For Covid-19 Vaccines
                       3.3.1 U.S. And Germany On The Forefront
                   3.4 Covax Initiative
                   3.5 Total Addressable Market: Covid-19 Vaccines Market
                       3.5.1 North America
                       3.5.2 Europe
                       3.5.3 Asia Pacific
                       3.5.4 Row
                   3.6 Key Challenges Of Vaccine Development
                       3.6.1 Hurdles In Expedited Programs
                           3.6.1.1 Mutation Monitoring And Evaluation
                           3.6.1.2 Regulatory Restraints
                       3.6.2 Challenges In Vaccine Implementation
                           3.6.2.1 Expected Glass Shortage
                   3.7 Impact Analysis On Other Vaccine’s Market
                       3.7.1 Impact Of Covid-19 On Vaccine Supplies
                           3.7.1.1 Covid-19 Disrupts Vaccine Delivery
                       3.7.2 Impact Of Covid-19 On Vaccine-Preventable Diseases And Antibiotic Resistance
                   3.8 Pricing Analysis
                   3.9 Vaccine Manufacturing Approaches By Different Companies
                       3.9.1 Sanofi
                       3.9.2 Gsk
                       3.9.3 Greffex
                       3.9.4 Novovax
                       3.9.5 Arcturus Therapeutics
                   3.10 Vaccine Types
                       3.10.1 Virus Like Particle (Vlp) Vaccines
                       3.10.2 Whole Virus Vaccines
                       3.10.3 Subunit (Protein) Vaccines
                       3.10.4 Antibodies
                       3.10.5 Viral Vector Vaccines
                       3.10.6 Mrna/Dna Vaccines
                   3.11 Leading Vaccine Platforms
                       3.11.1 Live Attenuated
                       3.11.2 Inactivated
                       3.11.3 Replicating Or Non-Replicating Vector Vaccines
                       3.11.4 Nucleic Acid Vaccines (Dna/Mrna)
                   3.12 Role Of Contract Manufacturers
                   3.13 Strategies To Consider Before Investing In The Space
                   3.14 Investor Confidence
                       3.14.1 Public Investors
                       3.14.2 Private Investors
                   3.15 Regulatory Changes Specific To Covid-19
                   3.16 Covid-19 Vaccine R&D Landscape
                       3.16.1 Pipeline Analysis, By Technology/ Platform
                           3.16.1.1 Mrna-Based
                           3.16.1.2 Dna-Based
                           3.16.1.3 Inactivated Whole-Virus Vaccine
                           3.16.1.4 Adenovirus Viral Vector
                           3.16.1.5 Lentivirus Vector
                           3.16.1.6 Others
                       3.16.2 Pipeline Analysis, By Sponsor Type
                           3.16.2.1 Non-Profit
                           3.16.2.2 Public
                           3.16.2.3 Academic
                           3.16.2.4 Private
                       3.16.3 Pipeline Analysis, By Geography
                           3.16.3.1 North America
                           3.16.3.2 Europe
                           3.16.3.3 Asia Pacific
                           3.16.3.4 Row
                       3.16.4 Pipeline Analysis, By Company
                           3.16.4.1 CanSino Biologics
                           3.16.4.2 Vaccitech
                           3.16.4.3 Pfizer Inc.
                           3.16.4.4 Moderna, Inc.
                           3.16.4.5 SHIONOGI Co., Ltd.
                           3.16.4.6 Johnson & Johnson Services, Inc.
                           3.16.4.7 GlaxoSmithKline plc.
                           3.16.4.8 GeoVax Labs, Inc.
                           3.16.4.9 CureVac AG
                           3.16.4.10 Baylor College of Medicine
                           3.16.4.11 Sirnaomics, Inc.
                           3.16.4.12 Stermirna Therapeutics Co., Ltd.
                           3.16.4.13 Regeneron Pharmaceuticals, Inc.
                           3.16.4.14 Novavax
                           3.16.4.15 Nanoviricides, Inc.
                           3.16.4.16 The Jenner Institute
                           3.16.4.17 Inovio Pharmaceuticals
                           3.16.4.18 Imperial College London
                           3.16.4.19 Heat Biologics, Inc.
                           3.16.4.20 Vir Biotechnology
                           3.16.4.21 Vaxart, Inc.
                           3.16.4.22 The University of Queensland
                           3.16.4.23 Takeda Pharmaceutical Company Limited
                           3.16.4.24 Stemirna Therapeutics Co., Ltd
                           3.16.4.25 Shanghai East International Medical Center
                           3.16.4.26 Genexine, Inc.
                           3.16.4.27 Duke-NUS
                           3.16.4.28 Bharat Biotech
                           3.16.4.29 The National Institute of Virology
                           3.16.4.30 Anhui Zhifei Longcom Biopharmaceutical
                           3.16.4.31 The Institute of Microbiology of the Chinese Academy of Sciences
                           3.16.4.32 Institute Of Microbiology Chinese Academy of Sciences
                           3.16.4.33 The Faustman Lab At Massachusetts General Hospital (MGH)
                           3.16.4.34 China National Biotech Group Co Ltd (CNBG)
                           3.16.4.35 Serum Institute of India
                           3.16.4.36 IQVIA
                           3.16.4.37 AstraZeneca
                           3.16.4.38 The University of Oxford
                           3.16.4.39 BioNTech
                           3.16.4.40 Anhui Zhifei Longcom Biopharmaceutical
                           3.16.4.41 The Institute of Microbiology of the Chinese Academy of Sciences
                           3.16.4.42 Wuhan Institute of Biological Products Co Ltd
                           3.16.4.43 Murdoch Children's Research Institute
                           3.16.4.44 Sinovac Biotech Ltd.
                           3.16.4.45 China National Pharmaceutical Group Co., Ltd. (Sinopharm)
                           3.16.4.46 Takis S.r.l.
                           3.16.4.47 Adimmune Corporation
                           3.16.4.48 ReiThera Srl
                           3.16.4.49 AnGes, Inc.
                           3.16.4.50 Hoth Therapeutics



What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.